Management of Diabetic Nephropathy with Persistent Albuminuria and Reduced eGFR

Pharmacologic Therapy

• Initiate a renin‑angiotensin system blocker (ACE inhibitor or ARB) immediately in any adult with diabetes, persistent albuminuria ≥ 30 mg/g and eGFR < 60 mL/min/1.73 m², regardless of blood‑pressure level. This first‑line recommendation is supported by the American Diabetes Association (ADA) Standards of Care (Grade A when albuminuria ≥ 300 mg/g; Grade B for albuminuria 30‑299 mg/g). 1

• Do not discontinue the ACE inhibitor/ARB if serum creatinine rises ≤ 30 % in the absence of volume depletion; the rise reflects a benign hemodynamic effect. 1

• Add an SGLT2 inhibitor with proven renal or cardiovascular benefit when eGFR ≥ 30 mL/min/1.73 m² and albuminuria > 300 mg/g (Grade A evidence). The 2022 ADA/KDIGO consensus strongly recommends this class for type 2 diabetes and CKD, and advises continuation even as eGFR falls below 30 mL/min/1.73 m². [1] [2]

• SGLT2 inhibitors also confer additional cardiovascular risk reduction when eGFR > 30 mL/min/1.73 m² or albuminuria > 300 mg/g. 1

• Consider a GLP‑1 receptor agonist with proven cardiovascular benefit if individualized glycemic targets are not achieved with metformin and/or an SGLT2 inhibitor, or if those agents are contraindicated. GLP‑1 agonists reduce progression of albuminuria and lower cardiovascular events in CKD patients at high cardiovascular risk. [1] [2]

• Add a non‑steroidal mineralocorticoid receptor antagonist (MRA) when eGFR ≥ 25 mL/min/1.73 m², serum potassium is within normal range, and albuminuria ≥ 30 mg/g, to obtain further kidney and cardiovascular protection. 2

Glycemic Targets

• Aim for HbA1c < 7 % in most adults with diabetic kidney disease to slow disease progression (Grade A evidence). 1

• Intensive glycemic control delays the onset of microalbuminuria and slows progression from micro‑ to macro‑albuminuria. 3

• Individualize glycemic goals based on hypoglycemia risk, life expectancy, and comorbid conditions. 2

Blood‑Pressure Management

• Target blood pressure < 130/80 mmHg in adults with diabetes and CKD, especially when albuminuria is present. This target is endorsed by the KDIGO‑ADA consensus (Grade A for renal risk reduction). [2] [1]

• Blood‑pressure optimization (Grade A) reduces the risk of CKD progression and cardiovascular events. [1] [3]

• ACE inhibitors or ARBs serve a dual purpose: renoprotection and blood‑pressure control. 1

Dietary Recommendations

• Limit dietary protein to approximately 0.8 g per kilogram of body weight per day (the recommended daily allowance) for adults with non‑dialysis‑dependent CKD. 1

Monitoring Strategy

• Check serum creatinine and potassium 2–4 weeks after initiating or titrating an ACE inhibitor or ARB; an increase in creatinine up to 30 % is acceptable. 1

• Measure urine albumin‑to‑creatinine ratio (UACR) and eGFR every six months in patients with albuminuria > 30 mg/g or eGFR < 60 mL/min/1.73 m². [1] [2]

• Perform periodic serum creatinine and potassium assessments while patients are on ACE inhibitors, ARBs, or diuretics. 1

Nephrology Referral

• Refer to a nephrologist when eGFR declines to < 30 mL/min/1.73 m² for planning of renal replacement therapy. 3

• Consider earlier referral (eGFR < 60 mL/min/1.73 m²) if hypertension or hyperkalemia is difficult to manage. 3

• Early nephrology referral is associated with lower health‑care costs, improved quality of care, and delayed initiation of dialysis. 3

Implementation Considerations

• Avoid therapeutic inertia; most adults with diabetes and CKD require simultaneous initiation of multiple interventions (renin‑angiotensin blockade, SGLT2 inhibition, blood‑pressure control, and glycemic optimization). 2

• The strongest evidence base derives from the 2022 ADA/KDIGO consensus report and the 2021 ADA Standards of Care; the addition of SGLT2 inhibitors represents a major advancement over earlier guidelines (2004). [2] [1] 3

Management of High Urine Albumin-to-Creatinine Ratio in Diabetic Patients

Assessment and Monitoring

• The American Diabetes Association recommends that UACR should be assessed at least annually in all patients with type 2 diabetes regardless of treatment and in type 1 diabetes with duration ≥5 years 4, 5
• For patients with established diabetic kidney disease, UACR should be monitored 1-4 times per year depending on disease stage 4, 6
• Due to high biological variability in urinary albumin excretion, two of three specimens collected within a 3-6 month period should be abnormal before confirming the diagnosis of albuminuria 7
• Factors that can temporarily elevate UACR include exercise within 24 hours, infection, fever, congestive heart failure, marked hyperglycemia, menstruation, and marked hypertension 7

Classification of Albuminuria

• Normal UACR is defined as <30 mg/g creatinine 8, 7
• Moderately increased albuminuria is defined as 30-299 mg/g creatinine 4, 6
• Severely increased albuminuria is defined as ≥300 mg/g creatinine 4, 6

Treatment Algorithm

• The American Diabetes Association recommends renin-angiotensin system blockade with an ACE inhibitor or ARB for moderately increased albuminuria (30-299 mg/g) 4, 5
• For severely increased albuminuria (≥300 mg/g), ACE inhibitor or ARB is strongly recommended 4, 5
• Optimize glucose control to reduce risk or slow progression of diabetic kidney disease 4, 9
• Optimize blood pressure control to reduce risk or slow progression of diabetic kidney disease 4, 6
• Target blood pressure goals should be individualized based on cardiovascular risk 10

Additional Considerations

• Dietary protein intake should be approximately 0.8 g/kg body weight per day for patients with non-dialysis dependent diabetic kidney disease 6, 9
• For patients on dialysis, higher levels of dietary protein intake should be considered 6, 9

Referral to Nephrology

• Refer patients to a nephrologist if eGFR <30 mL/min/1.73m² 7
• Prompt referral is warranted for uncertainty about kidney disease etiology, difficult management issues, or rapidly progressing kidney disease 7

Clinical Pearls and Pitfalls

• ACE inhibitors or ARBs are not recommended for primary prevention of diabetic kidney disease in patients with normal blood pressure, normal UACR (<30 mg/g), and normal eGFR 8, 7
• Do not discontinue renin-angiotensin system blockade for minor increases in serum creatinine (<30%) in the absence of volume depletion 9